Literature DB >> 1679332

Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse.

T W Kay1, I L Campbell, L C Harrison.   

Abstract

Pancreatic beta cell destruction in the non-obese diabetic (NOD) mouse is mediated by T lymphocytes and macrophages and accelerated by cyclophosphamide. We purified pancreatic T lymphocytes from the NOD mouse for comparative phenotypic and functional analysis with T lymphocytes from spleen, peripheral blood and regional lymph nodes. Pancreatic T lymphocytes from NOD-Wehi mice, which have an incidence of spontaneous diabetes of less than 5%, had a CD4:CD8 ratio of 1.25 +/- 0.23 compared with 2.44 +/- 0.31 for peripheral blood lymphocytes. After cyclophosphamide, the CD4:CD8 ratio of pancreatic lymphocytes increased to 2.30 +/- 0.24 at day 7. T lymphocytes bearing IL-2 receptors increased two- to three-fold in number and their secretion of GM-CSF/IL-3 and IFN-gamma increased to a maximum on day 7. Pancreatic insulin content and mRNA levels declined sharply between days 10 and 12, at which time the majority of pancreatic T lymphocytes in hyperglycaemic mice were CD8+ (CD4:CD8 ratio 0.63 +/- 0.04 compared to 4.14 +/- 1.05 in peripheral blood). The pancreatic T lymphocyte CD4:CD8 ratio in prediabetic NOD-Lt mice, which have an incidence of spontaneous diabetes of about 60% at 150 days, was similar to that in untreated NOD-Wehi mice, but 25% of their pancreatic CD8 T lymphocytes were IL-2-receptor positive. Thus, significant changes in the phenotype of NOD pancreatic T lymphocytes following cyclophosphamide were not reflected in peripheral blood or spleen T lymphocytes. The earliest change after cyclophosphamide was an increase in activated, predominantly CD4+ T lymphocytes; with the development of beta cell destruction and hyperglycaemia, pancreatic T lymphocytes were, as in human IDDM, predominantly CD8+.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679332     DOI: 10.1016/0896-8411(91)90023-6

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  11 in total

1.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

2.  Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes.

Authors:  L C Harrison; S X Chu; H J DeAizpurua; M Graham; M C Honeyman; P G Colman
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

3.  Histopathological changes in insulin, glucagon and somatostatin cells in the islets of NOD mice during cyclophosphamide-accelerated diabetes: a combined immunohistochemical and histochemical study.

Authors:  Shiva Reddy; Praneeti Pathipati; Yan Bai; Elizabeth Robinson; Jacqueline M Ross
Journal:  J Mol Histol       Date:  2005-05       Impact factor: 2.611

4.  Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-gamma antibody.

Authors:  T W Kay; I L Campbell; L Oxbrow; L C Harrison
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

5.  A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice.

Authors:  Ming S Lin; Hubert M Tse; Meghan M Delmastro; Suzanne Bertera; Caterina T Wong; Robert Lakomy; Jing He; Martha M Sklavos; Gina M Coudriet; Massimo Pietropaolo; Massimo M Trucco; Jon D Piganelli
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

Review 7.  The immunologic insult in type 1 diabetes.

Authors:  M C Honeyman; L C Harrison
Journal:  Springer Semin Immunopathol       Date:  1993

8.  High serum levels of soluble CD8 in insulin-dependent diabetes.

Authors:  E Di Cesare; M Previti; M C Ingemi; G F Bagnato; D Cucinotta
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  Galantamine Attenuates Type 1 Diabetes and Inhibits Anti-Insulin Antibodies in Nonobese Diabetic Mice.

Authors:  William M Hanes; Peder S Olofsson; Kevin Kwan; LaQueta K Hudson; Sangeeta S Chavan; Valentin A Pavlov; Kevin J Tracey
Journal:  Mol Med       Date:  2015-08-17       Impact factor: 6.354

10.  IFN-γ receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells.

Authors:  Zuoan Yi; Li Li; Alaina Garland; Qiuming He; Haidong Wang; Jonathan D Katz; Roland Tisch; Bo Wang
Journal:  Eur J Immunol       Date:  2012-08       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.